Participant flow

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib · Source last updated 2022-09-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Phase 1, Level 1: Ruxolitinib 5 mg twice daily

   id

   FG000

   title

   Phase 1, Level 1: Ruxolitinib 10 mg

2. description

   Phase 1 Level 2: Ruxolitinib 10 mg twice daily

   id

   FG001

   title

   Phase 1 Level 2: Ruxolitinib 20 mg

3. description

   Phase 1 Level 3: Ruxolitinib 15 mg twice daily

   id

   FG002

   title

   Phase 1 Level 3: Ruxolitinib 30 mg

4. description

   Phase 1 Level 4: 20 mg Ruxolitinib twice daily

   id

   FG003

   title

   Phase 1 Level 4: 40 mg Ruxolitinib

5. description

   Phase II: Treatment at Maximum Tolerated Dose (MTD).

   id

   FG004

   title

   Phase 2: Maximum Tolerated Dose - Ruxolitinib

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         4

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         5

      5. group Id

         FG004

         num Subjects

         30

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         6

      2. group Id

         FG001

         num Subjects

         4

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         5

      5. group Id

         FG004

         num Subjects

         30

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice